Haemonetics (HAE) Projected to Announce Earnings on Thursday

Haemonetics (NYSE:HAE) is expected to be announcing its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect Haemonetics to announce earnings of $1.08 per share and revenue of $327.8930 million for the quarter. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Individuals are encouraged to explore the company’s upcoming Q1 2027 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.24 EPS. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Haemonetics Price Performance

Shares of NYSE HAE opened at $85.37 on Wednesday. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $88.58. The business has a fifty day moving average price of $75.90 and a two-hundred day moving average price of $66.21. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The stock has a market capitalization of $3.88 billion, a PE ratio of 42.26, a P/E/G ratio of 1.75 and a beta of 0.52.

Institutional Investors Weigh In On Haemonetics

Hedge funds have recently modified their holdings of the company. Quantinno Capital Management LP increased its holdings in Haemonetics by 9.0% in the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock worth $261,000 after purchasing an additional 289 shares in the last quarter. UMB Bank n.a. raised its position in Haemonetics by 110.9% in the fourth quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 306 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in shares of Haemonetics during the fourth quarter valued at about $26,000. Empowered Funds LLC boosted its stake in shares of Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 372 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on HAE shares. Citigroup reaffirmed a “buy” rating on shares of Haemonetics in a report on Wednesday, July 29th. BTIG Research reiterated a “buy” rating and issued a $84.00 target price on shares of Haemonetics in a research report on Friday, June 26th. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Mizuho increased their target price on shares of Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Finally, Barrington Research decreased their price target on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and an average price target of $78.89.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.